Clinical response and follow-up treatment are summarized below:

IVIG Courses (Mean/Range, in Months) Response to IVIG (N - %) Therapy Concurrent with IVIG Additional Therapy if NR/PR Relapse Among SR IVIG Treatment of Relapse in SR Clinical Course After IVIG Treatment of Relapse Progression to CDM
All: 4.8 (1-15)
SR: 5.3 (3-15)
NR: 4(15%)
PR: 4(15%)
SR: 19(70%)
All: 17(63%)
TAC: 2(7%)
CLQ: 1(4%)
HCQ: 9(33%)
SGC: 6(22%)
 SGC: 7(26%)
MTX: 1(4%)
MMF: 1(4%)
HCQ: 2(7%)
10 (53%) 6 (60%) Required Multiple courses of IVIG: 3/6
Treatment following IVIG Retreatment
SGC=2, MTX=2
6/27 (22%)
0/9 non-relapsed SR
2/10 relapsed SR
4/8 NR or PR

Key:ADM: Amyopathic Dermatomyositis: Cutaneous findings for at least 6 months, without clinical or laboratory evidence of muscle diseasehDM: Hypomyopathic Dermatomyositis: Cutaneous findings with subclinical muscle disease (i.e. asymptomatic and normal exam with abnormal muscle enzymes and/or abnormal EMG)pDM: Premyopathic Dermatomyositis: Cutaneous findings for less than 6 months, without clinical or laboratory evidence of muscle diseaseCR-CDM: Cutaneous relapse of Classical Dermatomyositis (relapse involving only cutaneous manifestations, with previous muscle involvement)ILD: Interstitial Lung Disease; TGC: topical glucocorticoids; TAC: topical tacrolimus; SGC: Systemic Glucocorticoids; CLQ: Chloroquine; HCQ: Hydroxychloroquine; MTX: Methotrexate; MMF: Mycophenolate Mofetil; AZA: Azathioprine; SR: significant response, defined by the investigators as a complete or near-complete response; NR: no response; PR: Partial Response.